Testosterone booster for gynaecomastia is a topic that attracts considerable interest, yet the evidence supporting this approach is weak and the risks are real. Gynaecomastia — the benign enlargement of glandular breast tissue in males — arises from an imbalance between oestrogen and testosterone activity. Whilst it may seem logical that raising testosterone could correct this imbalance, over-the-counter testosterone supplements are not licensed medicines, lack robust clinical evidence, and can paradoxically worsen breast tissue growth through aromatisation. This article explores the causes of gynaecomastia, the evidence around testosterone supplements, UK regulatory guidance, and the clinically recognised treatment options available.

What Causes Gynaecomastia and the Role of Hormonal Imbalance

Gynaecomastia develops when oestrogen activity exceeds testosterone activity in breast tissue, caused by factors including puberty, hypogonadism, medications, liver disease, obesity, and endocrine tumours.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, affecting one or both breasts. It is a relatively common condition, occurring at various life stages — including infancy, puberty, and older adulthood — and is primarily driven by an imbalance between oestrogen and testosterone activity in breast tissue.

In healthy males, testosterone suppresses breast tissue growth whilst oestrogen promotes it. When this balance is disrupted — whether through reduced testosterone production, increased oestrogen levels, or heightened sensitivity of breast tissue to oestrogen — gynaecomastia can develop.

Common underlying causes include:

• Puberty: Transient hormonal fluctuations are the most frequent cause in adolescents, typically resolving within one to two years.

• Hypogonadism: Conditions such as Klinefelter syndrome or age-related testosterone decline can lower circulating testosterone.

• Endocrine disorders: Hyperthyroidism, hyperprolactinaemia, and adrenal or testicular tumours (including hCG-secreting neoplasms) can all disrupt the oestrogen-to-testosterone ratio.

• Medications: A wide range of drugs are well-recognised triggers, including spironolactone, cimetidine, anabolic steroids, some antipsychotics, 5-alpha-reductase inhibitors (finasteride, dutasteride), antiandrogens (bicalutamide), GnRH analogues, and certain antiretrovirals. If you are taking a prescribed medicine that you suspect may be contributing to gynaecomastia, do not stop it without first discussing this with your prescriber.

• Liver disease or renal failure: These conditions can alter hormone metabolism, increasing oestrogen relative to testosterone.

• Obesity: Excess adipose tissue converts androgens to oestrogens via aromatase enzymes, raising oestrogen levels.

• Chronic alcohol use: Associated with altered hepatic hormone metabolism and reduced testosterone production.

It is important to distinguish true gynaecomastia — involving glandular tissue — from pseudogynaecomastia, which is caused by fatty tissue accumulation without glandular proliferation. A thorough clinical assessment is essential to identify any reversible or treatable underlying cause before considering any intervention.

Relevant UK resources: NICE CKS: Gynaecomastia; NHS: Enlarged male breasts (gynaecomastia).

Can Testosterone Boosters Help with Gynaecomastia?

Testosterone boosters are not recommended for gynaecomastia; they lack robust clinical evidence and can worsen the condition by converting androgens to oestrogens via aromatisation.

The idea that testosterone boosters might reduce gynaecomastia is based on the premise that raising testosterone levels could restore the oestrogen-to-testosterone ratio in favour of androgen dominance, thereby reducing breast tissue stimulation. However, the reality is considerably more complex, and this approach carries significant risks.

Over-the-counter testosterone boosters — typically marketed as supplements containing ingredients such as D-aspartic acid, fenugreek, zinc, or tribulus terrestris — are not licensed medicines. Their ability to meaningfully raise serum testosterone in clinically relevant amounts is not well supported by robust clinical evidence. Most studies examining these ingredients are small, short-term, and of low methodological quality, with inconsistent results across trials.

More critically, some testosterone precursors and anabolic compounds can actually worsen gynaecomastia. This occurs because excess androgens can be converted to oestrogens via the aromatase enzyme — a process known as peripheral aromatisation. Anabolic steroids, in particular, are a well-documented cause of gynaecomastia rather than a treatment for it.

It is important to distinguish unregulated over-the-counter supplements from licensed prescription testosterone replacement therapy (TRT). TRT is a prescription-only medicine in the UK, available only after a confirmed diagnosis of biochemical hypogonadism — typically defined as low serum testosterone on two separate early-morning samples, alongside relevant symptoms and signs. TRT is not licensed or recommended as a treatment for gynaecomastia in isolation.

There is currently no official clinical guidance recommending testosterone boosters as a treatment for gynaecomastia. Individuals who self-medicate with such supplements without medical supervision risk hormonal disruption, cardiovascular strain, and delayed diagnosis of an underlying condition. Anyone concerned about gynaecomastia should seek a formal medical evaluation rather than attempting self-treatment with unregulated supplements.

Relevant UK resources: MHRA safety communications on unlicensed testosterone products and SARMs in supplements; eMC SmPCs for licensed testosterone products (e.g., Testogel, Nebido, Sustanon); NICE CKS: Testosterone deficiency.

Evidence and Safety Concerns Around Testosterone Supplements

Most commercially available testosterone boosters lack sufficient clinical evidence for their claimed effects, and carry risks including cardiovascular harm, endocrine suppression, hepatotoxicity, and gynaecomastia exacerbation.

The market for testosterone-boosting supplements is large and, whilst such products are regulated as foods in the UK (under Food Standards Agency and Trading Standards frameworks), they are not licensed as medicines. Unlike licensed medicines, food supplements do not require proof of efficacy before being placed on the market, though manufacturers do have obligations regarding safety. This means consumers cannot assume these products are effective, and the absence of a medicines licence does not guarantee safety.

From an evidence standpoint, a 2021 systematic review published in the World Journal of Men's Health (Balasubramanian et al.) found that the majority of commercially available testosterone boosters lacked sufficient clinical evidence to support their claimed effects on serum testosterone. Ingredients such as tribulus terrestris and D-aspartic acid showed inconsistent results across trials, with several studies demonstrating no significant hormonal change.

Safety concerns associated with testosterone-related supplements include:

• Cardiovascular risk: Elevated androgens — particularly from anabolic-androgenic steroid misuse — are associated with dyslipidaemia, left ventricular hypertrophy, and increased thrombotic risk. This is distinct from the cardiovascular safety profile of appropriately prescribed and monitored licensed TRT, which is subject to ongoing MHRA and EMA review.

• Hepatotoxicity: Certain oral anabolic compounds carry a risk of liver damage.

• Endocrine suppression: Exogenous androgens can suppress the hypothalamic-pituitary-gonadal (HPG) axis, paradoxically reducing natural testosterone production.

• Gynaecomastia exacerbation: As noted, aromatisation of excess androgens can increase oestrogen levels and worsen breast tissue growth.

• Contamination: The MHRA has previously issued warnings about supplements found to contain undeclared anabolic steroids, selective androgen receptor modulators (SARMs), or other prohibited substances.

Patients and healthcare professionals should report suspected side effects of any medicine, herbal remedy, or supplement to the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk).

Patients should be advised to exercise caution with any product making hormonal claims and to consult a healthcare professional before use, particularly if they have pre-existing cardiovascular, hepatic, or endocrine conditions.

Relevant UK resources: FSA guidance on food supplements regulation; MHRA Drug Safety Updates and enforcement notices on SARMs and anabolic steroids in supplements; MHRA Yellow Card scheme.

MHRA and NHS Guidance on Hormonal Treatments for Gynaecomastia

The MHRA and NHS do not support testosterone boosters for gynaecomastia; licensed TRT is approved only for confirmed biochemical hypogonadism, not as a standalone gynaecomastia treatment.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates licensed medicines, including hormone therapies. The MHRA has issued multiple alerts regarding unlicensed testosterone products and supplements containing undeclared active substances, urging consumers to purchase only from reputable, regulated sources.

The NHS acknowledges that gynaecomastia is common and often resolves without treatment, particularly in adolescents. For persistent or symptomatic cases, the NHS recommends a structured clinical approach beginning with identification and removal of any causative factors — such as offending medications or treatment of underlying disease — before considering pharmacological or surgical intervention.

Licensed testosterone replacement therapy (TRT) products available in the UK (such as Testogel, Nebido, and Sustanon) are approved for the treatment of hypogonadism in adult males where testosterone deficiency has been confirmed by clinical features and biochemical testing. Their Summary of Product Characteristics (SmPC), available via the electronic Medicines Compendium (eMC), and the relevant European Medicines Agency (EMA) European Public Assessment Reports (EPARs) confirm that TRT is not licensed as a treatment for gynaecomastia in isolation. Its use is reserved for men with a confirmed hormonal deficiency, diagnosed through blood testing and clinical assessment.

NICE does not currently have a dedicated standalone guideline for gynaecomastia management, but NICE CKS: Gynaecomastia provides evidence-based guidance for primary care assessment, investigation, and referral. Relevant NICE guidance on male hypogonadism and endocrine assessment also informs clinical practice.

Prescribing testosterone outside of licensed indications — for example, for cosmetic or bodybuilding purposes — is not supported by MHRA or NHS frameworks. Where off-label prescribing is considered for any indication, clinicians are expected to follow GMC guidance on good prescribing practice, ensuring there is a responsible evidence base and that the patient is fully informed.

Relevant UK resources: NICE CKS: Gynaecomastia; eMC SmPCs for Testogel, Nebido, Sustanon; EMA EPARs for testosterone products; MHRA Drug Safety Update on testosterone; GMC: Good practice in prescribing and managing medicines and devices.

When to See a GP About Gynaecomastia and Hormone Levels

Men should see a GP if they have unilateral breast enlargement, a firm lump, nipple discharge, rapid onset, or symptoms suggesting hypogonadism; urgent cancer referral applies per NICE NG12.

Many cases of gynaecomastia are benign and self-limiting, but there are important clinical scenarios in which prompt medical review is warranted. Individuals should be encouraged to consult their GP if they notice any of the following:

• Unilateral or asymmetric breast enlargement, particularly if associated with a firm or irregular lump

• Breast pain or tenderness that is persistent or worsening

• Nipple discharge, which may indicate an underlying pathology

• Rapid onset of breast tissue growth in an adult male

• Associated symptoms such as fatigue, reduced libido, erectile dysfunction, or mood changes that may suggest hypogonadism

• Recent use of anabolic steroids or testosterone supplements that may have triggered or worsened the condition

• Prepubertal onset of breast tissue enlargement, or gynaecomastia persisting beyond two years in an adolescent, or features suggesting delayed puberty — these warrant paediatric endocrine assessment

Urgent referral (2-week wait): In line with NICE NG12 (Suspected cancer: recognition and referral), GPs should consider an urgent suspected cancer referral for men aged 30 and over with an unexplained breast lump, and for men aged 50 and over with unilateral nipple changes (such as discharge, retraction, or skin changes). Suspicious breast findings should be referred to a one-stop breast clinic.

A GP will typically take a thorough history, including a full medication review, and arrange relevant investigations. These should include two early-morning (before 11:00) fasting serum testosterone measurements on separate days, together with luteinising hormone (LH), follicle-stimulating hormone (FSH), and oestradiol. Where testosterone results are borderline, sex hormone-binding globulin (SHBG) and albumin may be measured to estimate free testosterone. Thyroid-stimulating hormone (TSH) should be checked to exclude hyperthyroidism, and serum human chorionic gonadotrophin (hCG) considered where a neoplastic cause is suspected. Liver function tests and renal function are also appropriate. Testicular examination is essential; testicular ultrasound or mammography may be indicated to exclude malignancy.

Whilst male breast cancer is rare — accounting for less than 1% of all breast cancers in the UK — it should always be considered in the differential diagnosis, particularly in older men with a new unilateral breast mass.

Relevant UK resources: NICE NG12: Suspected cancer: recognition and referral; NICE CKS: Gynaecomastia; NHS: Enlarged male breasts (gynaecomastia).

Clinically Recognised Treatment Options Available in the UK

Evidence-based options include watchful waiting, removal of causative medications, off-label tamoxifen or aromatase inhibitors in early disease, and subcutaneous mastectomy for longstanding fibrotic gynaecomastia.

For men with persistent or symptomatic gynaecomastia, several evidence-based treatment options are available through the NHS and private healthcare pathways in the UK. The most appropriate approach depends on the underlying cause, duration of the condition, and the degree of patient distress. Treatment decisions should be made collaboratively between the patient and their clinician, with psychological support considered where body image or mental health is significantly affected.

Watchful waiting remains the first-line approach for pubertal gynaecomastia, given its high rate of spontaneous resolution. In cases where a causative medication has been identified, discontinuation or substitution — where clinically safe and agreed with the prescriber — is recommended as an initial step. Patients should not stop any prescribed medicine without first discussing this with their prescriber.

Pharmacological options are most effective when used early in the course of the condition, typically within the first six to twelve months, before fibrotic changes become established. All pharmacological treatments for gynaecomastia are used off-label in the UK; patients should be informed of this and of the relevant risks and benefits:

• Tamoxifen (off-label): A selective oestrogen receptor modulator (SERM) that blocks oestrogen action in breast tissue. It has demonstrated efficacy in reducing breast volume and tenderness in several clinical studies. Risks include venous thromboembolism (VTE), hot flushes, and, rarely, endometrial effects. See BNF and eMC SmPC for full prescribing information.

• Raloxifene (off-label): Another SERM occasionally used in this context, though evidence is more limited than for tamoxifen. VTE risk applies similarly.

• Aromatase inhibitors (e.g., anastrozole, off-label): These reduce peripheral conversion of androgens to oestrogens. Risks include bone loss, arthralgia, and hot flushes. See BNF and eMC SmPC for full prescribing information.

• Danazol (off-label): An androgen with anti-gonadotrophic properties, occasionally used where other options are unsuitable. Its use is limited by a significant adverse effect profile, including virilisation, hepatotoxicity, and dyslipidaemia.

Surgical intervention — specifically subcutaneous mastectomy or liposuction — is considered for longstanding gynaecomastia (typically beyond 12 months) where fibrotic changes have occurred and medical therapy is unlikely to be effective. In the UK, surgery for gynaecomastia may be available on the NHS where there is significant psychological impact, though eligibility criteria vary by Integrated Care Board (ICB).

Patients should be advised that unregulated testosterone boosters are not a recognised treatment for gynaecomastia and may carry meaningful risks. A structured, medically supervised approach remains the safest and most effective pathway.

Relevant UK resources: NICE CKS: Gynaecomastia (management); BNF monographs: Tamoxifen, Raloxifene, Anastrozole, Danazol; eMC SmPCs: Tamoxifen, Raloxifene, Anastrozole.

Frequently Asked Questions